Skip to content
Disclosery

Checkpoint Capital L.P.

Follow

13F filer, CIK 1977548, SAN FRANCISCO, CA

Checkpoint Capital L.P. reported $298,471,395 across 10 holdings for the quarter ended 2025-09-30, in a 13F-HR filed 2025-11-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001977548-25-000008

Period
2025-09-30
Reported value
$298M
Holdings
10
Top 10 weight
100%
New
3
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IRONadded+165,000$10.9M
CRNXnew+260,000$10.8M
RVMDadded+212,300$9.91M
STOKnew+212,049$4.98M
CORTadded+48,414$4.02M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RYTMreduced-296,293-$29.9M
SEPNreduced-303,315-$5.71M
PTGXexited-81,311-$4.49M
KYMRreduced-45,241-$2.56M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2025

Share positions as resolved from 13F-HR 0001977548-25-000008, largest first. % of portfolio is the value over $298,471,395, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ARGXARGENX SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 92,500 shares; 2024Q4: 92,500 shares; 2025Q1: 115,000 shares; 2025Q2: 149,977 shares; 2025Q3: 150,000 shares 150,000$111M37.07%+23Timeline
RYTMRHYTHM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 663,381 shares; 2024Q4: 727,982 shares; 2025Q1: 907,240 shares; 2025Q2: 1,060,000 shares; 2025Q3: 763,707 shares 763,707$77.1M25.84%-296,293Timeline
CORTCORCEPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 5,000 shares; 2025Q2: 343,917 shares; 2025Q3: 392,331 shares 392,331$32.6M10.92%+48,414Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 25,543 shares; 2024Q4: 185,000 shares; 2025Q1: 243,311 shares; 2025Q2: 265,000 shares; 2025Q3: 430,000 shares 430,000$28.4M9.52%+165,000Timeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 210,000 shares; 2025Q1: 392,011 shares; 2025Q2: 280,000 shares; 2025Q3: 492,300 shares 492,300$23M7.7%+212,300Timeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 260,000 shares 260,000$10.8M3.63%newTimeline
SEPNSEPTERNA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 824,878 shares; 2025Q2: 586,473 shares; 2025Q3: 283,158 shares 283,158$5.33M1.78%-303,315Timeline
STOKSTOKE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 157,514 shares; 2024Q4: 305,387 shares; 2025Q1: 730,717 shares; 2025Q2: not reported; 2025Q3: 212,049 shares 212,049$4.98M1.67%newTimeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 77,535 shares; 2025Q1: 136,605 shares; 2025Q2: 106,991 shares; 2025Q3: 61,750 shares 61,750$3.5M1.17%-45,241Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 466,813 shares; 2024Q4: 20,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 37,587 shares 37,587$2.07M0.69%newTimeline

Sold out in Q3 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
PTGXPROTAGONIST THERAPEUTICS INC81,311$4.49Mshares

How Q3 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001977548-25-000008 base2025-11-14acceptance time not in the bulk data set